The intrinsic immunogenic properties of cancer cell lines
Nov 19, 2020 · In C57BL/6 mice and its derived cancer cell lines MC38 and B16, the other gene product, p15E, deriving from the gp70-precursor protein, has been shown to also give rise to …
Granzyme B nanoreporter for early monitoring of tumor …
Oct 2, 2020 · To test whether GNRs can enable monitoring of anti–PD-L1 treatment in real time, we performed efficacy studies in two different tumor models: WT-B16/F10 melanoma (poorly …
Tumor immunogenicity dictates reliance on TCF1 in CD8 - Cell Press
Sep 11, 2023 · Next, we implanted B16-F10 melanoma or MC38 colon carcinoma, both expressing ovalbumin (OVA) as a common ectopic tumor antigen in WT and TCF1 cKO mice. …
Anti-tumour immunity controlled through mRNA m - Nature
Feb 6, 2019 · To determine whether neoantigen-specific CD8 + T cell responses are generated in B16-OVA tumours, we analysed the frequency of tumour-infiltrating CD8 + T cells expressing …
Overcoming primary and acquired resistance to anti-PD-L1 ... - Nature
Oct 27, 2020 · Antitumor effect of anti-PD-L1 therapy was assessed in four syngeneic mouse tumor models: MC38 colon adenocarcinoma, B16 melanoma, and two triple-negative …
Organoid Modeling of the Tumor Immune Microenvironment
The corresponding MC38, B16-SIY, and A20-OVA tumor organoids were treated with function-blocking monoclonal anti-murine PD-1 or PD-L1 antibodies versus control IgG for 7 days …
Multimodal molecular imaging detects early responses to immune ...
Imaging [1,4-13C2] fumarate conversion to [1,4-13C2] malate showed a significant increase in necrotic cell death following treatment in the ICB-sensitive MC38 tumors, with essentially no …
Pharmacologic modulation of RNA splicing enhances anti-tumor …
Simultaneous indisulam and anti-PD1 therapy led to significantly reduced growth of both B16-F10 and MC38 tumors, which exceeded the effects of either drug alone (Figures 3A–3F and S3A) …
Unveiling the crossroads of STING signaling pathway and …
6 days ago · This method has demonstrated antitumor efficacy in the B16-OVA melanoma and MC38 colorectal cancer models . Potential metabolic targets for STING activation in the TME. …
B16 melanoma control by anti-PD-L1 requires CD8+ T cells and ... - PubMed
Jul 3, 2021 · Anti-programmed death ligand 1 (PD-L1) therapy has been beneficial in treating patients with certain cancers. Here, we tested whether anti-PD-L1 therapy is effective for …